Table 3.

Risk Factor Analysis to Identify Independent Predictors for Abnormal Liver Function at the End of Treatment in the Overall Patient Population and in Patients Who Received ≥75% of Their Course With 300 mg Micafungin 3 Times Weekly

Variable	Overall Patient Population (N = 104)			Micafungin 300 mg 3×/wk (N = 78)
	Univariate Analysisa			Univariate Analysisa
	OR	(95% CI)	P Value	OR	(95% CI)	P Value
Demographics
Age, ≥50 y vs <50 y	0.97	(.37–2.54)	.95	0.86	(.28–2.66)	.79
Sex, female	1.14	(.45–2.94)	.78	0.90	(.29–2.79)	.86
Race, white	0.57	(.21–1.54)	.26	0.68	(.20–2.29)	.53
Underlying disease
Acute leukemia vs other	1.59	(.60–4.19)	.35	1.45	(.46–4.57)	.52
Laboratory variables
Baseline abnormal liver function vs normalb	2.36	(.87–6.40)	.09	1.60	(.49–5.22)	.44
Baseline abnormal renal function vs normalc	0.92	(.24–3.60)	.91	0.49	(.06–4.26)	.52
Micafungin-related variables
Duration of micafungin administration
≤4 wk	1			1
5–8 wk	1.05	(.35–3.17)	.53	0.83	(.21–3.24)	.91
9–12 wk	0.37	(.07–1.86)	.19	0.57	(.10–3.15)	.50
>12 wk	1.10	(.25–4.86)	.57	1.24	(.20–7.53)	.60
Group 1 vs all othersd	0.65	(.23–1.82)	.41	NA	NA	NA
Micafungin daily dose estimate
<1.5 mg/kg	NA			1
1.5–2 mg/kg	NA			0.53	(.12–2.29)	.40
>2 mg/kg	NA			0.84	(.22–3.21)	.82

Liver impairment was defined as any of the following: aspartate and alanine aminotransferase >3 times the upper limit of normal (ULN) and alkaline phosphatase and total bilirubin >2 times the ULN.

Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio.

^a No variable was eligible to stay in the stepwise selection multivariate model.

^b Abnormal baseline liver function was defined as ≥1 of the following: aspartate and alanine aminotransferase >3 times the ULN and alkaline phosphatase and total bilirubin >2 times the ULN.

^c Abnormal baseline renal function was defined as creatinine clearance <50 mL/minute.

^d Group 1 included 78 patients who received 300 mg micafungin 3 times weekly for ≥75% of their course.